Intellia Therapeutics, Inc. (NTLA)
12.74
+0.06
(+0.47%)
USD |
NASDAQ |
Sep 04, 16:00
12.78
+0.04
(+0.31%)
After-Hours: 20:00
Intellia Therapeutics Research and Development Expense (Quarterly) : 80.50M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.50M |
| March 31, 2026 | 78.54M |
| December 31, 2025 | 86.27M |
| September 30, 2025 | 92.33M |
| June 30, 2025 | 94.54M |
| March 31, 2025 | 105.93M |
| December 31, 2024 | 114.31M |
| September 30, 2024 | 120.77M |
| June 30, 2024 | 111.61M |
| March 31, 2024 | 109.34M |
| December 31, 2023 | 106.52M |
| September 30, 2023 | 111.41M |
| June 30, 2023 | 113.11M |
| March 31, 2023 | 95.07M |
| December 31, 2022 | 98.00M |
| September 30, 2022 | 94.70M |
| June 30, 2022 | 88.36M |
| March 31, 2022 | 131.34M |
| December 31, 2021 | 69.28M |
| September 30, 2021 | 58.70M |
| June 30, 2021 | 57.25M |
| Date | Value |
|---|---|
| March 31, 2021 | 37.68M |
| December 31, 2020 | 36.63M |
| September 30, 2020 | 38.15M |
| June 30, 2020 | 36.20M |
| March 31, 2020 | 33.11M |
| December 31, 2019 | 31.73M |
| September 30, 2019 | 27.51M |
| June 30, 2019 | 25.46M |
| March 31, 2019 | 23.71M |
| December 31, 2018 | 19.92M |
| September 30, 2018 | 23.24M |
| June 30, 2018 | 23.47M |
| March 31, 2018 | 22.49M |
| December 31, 2017 | 21.17M |
| September 30, 2017 | 17.48M |
| June 30, 2017 | 15.56M |
| March 31, 2017 | 13.43M |
| December 31, 2016 | 11.33M |
| September 30, 2016 | 7.861M |
| June 30, 2016 | 7.423M |
| March 31, 2016 | 5.225M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Twist Bioscience Corp. | 18.02M |
| Beam Therapeutics, Inc. | 95.10M |
| Moderna, Inc. | 588.00M |
| Revolution Medicines, Inc. | 392.47M |
| Sana Biotechnology, Inc. | 36.08M |